Minims (Tropicamide)

Tropicamide blocks muscarinic (M3) receptors on the sphincter pupillae muscle, preventing acetylcholine‑induced contraction. This results in relaxation of the muscle, causing the pupil to enlarge (mydriasis) and the lens to lose its ability to focus (cycloplegia), thereby improving visual access for diagnostic and therapeutic purposes.

The dosage of Minims is determined by the prescribing eye care professional. Typically, one or two drops are instilled in the affected eye(s) as directed, with the interval and frequency set according to the specific diagnostic or procedural requirement.

Safety data for tropicamide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the Minims product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with agents such as phenylephrine or atropine, tropicamide has a rapid onset (within 15‑30 minutes) and a relatively short duration of action (4‑6 hours). This makes it suitable for routine diagnostic use, whereas longer‑acting agents may be preferred for therapeutic dilation in certain conditions.

Minims should be stored at ambient temperature, away from direct sunlight and moisture. Keep the bottle tightly closed when not in use, and retain it in the original packaging to protect the solution from contamination and degradation.

Minims is applied topically to the eye. The patient or clinician places the prescribed number of drops into the conjunctival sac of the target eye(s), usually after washing hands and avoiding contact between the dropper tip and any surface to maintain sterility.

The most serious adverse events include acute angle‑closure glaucoma, prolonged mydriasis, and severe allergic reactions such as eyelid swelling or rash. Patients should be monitored for signs of increased intra‑ocular pressure or systemic anticholinergic effects, and medical attention sought promptly if they occur.

Minims is contraindicated in individuals with known hypersensitivity to tropicamide or any formulation components, and it should be avoided in patients with narrow‑angle or uncontrolled glaucoma. Use in children requires special supervision, and clinicians should assess each patient’s suitability before prescribing.